ArticleTheranostics2026
Scalable manufacturing of human iPSC-derived functional liver organoids for acute liver failure treatment.
Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale: Acute liver failure (ALF) is a life-threatening disease associated with high mortality rates. Human induced pluripotent stem cell (hiPSC)-derived liver organoids (LOs) hold considerable promise as cell-based bridging therapies for ALF. However, the scalable production of highly consistent and mature LOs remains a major barrier to their clinical translation. In this study, we aimed to establish a scalable manufacturing platform for the reproducible generation of highly uniform and functionally mature liver organoids. Methods: We generated LOs from hiPSCs and established a differentiation platform designed for high-density LO production using low-attachment culture vessels combined with spin culture. The hepatic functions of conventionally cultured LOs (Con-LOs) and spin-cultured LOs (Spin-LOs) were evaluated using qPCR, albumin secretion assay, and detoxification assay. The molecular effects of spin culture on LO development were further analyzed using RNA sequencing. Furthermore, microwell bags were introduced to enhance manufacturing scalability. Finally, the LOs were transplanted into the intraperitoneal spaces of acetaminophen (APAP)-induced ALF mice to assess their therapeutic potential. Results: Compared to Con-LOs, Spin-LOs exhibited markedly elevated hepatic gene expression and significantly enhanced liver-specific functions. Mechanistically, spin culture enabled a metabolic transition from glycolysis to oxidative phosphorylation, thereby driving further functional maturation of liver organoids, resulting in improved synthetic, metabolic, and detoxification capacities. Moreover, integrating a microwell bag-based LO formation system with spin-culture-driven LO differentiation further promoted the efficiency and scalability of functional LO manufacturing. Importantly, these LOs provided short-term metabolic support following intraperitoneal transplantation into immunocompetent mice and significantly ameliorated APAP-induced liver failure. Conclusion: This study establishes a scalable manufacturing platform for the reproducible generation of highly uniform and functionally mature liver organoids. Our findings provide an evidence-supported foundation for their future clinical translation as cell-based bridging therapies for ALF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.